Additionally, dual inhibition of B7-H3 and CTLA-4 or PD-L1 promoted curative responses in murine models of castration-resistant prostate cancer, emphasizing the value of checkpoint combination strategies within molecularly defined tumor subtypes [155]. Here, CD276 is linked to prostate cancer.